AEM Holdings (SGX:AWX) has the strongest FY20E earnings visibility within our Singapore tech coverage.
Despite AEM’s Penang factory being closed through the movement control order in Malaysia from 18-Mar to 14-Apr, full year sales guidance of SGD360-380m is unchanged. As demand drivers appear intact, we believe a key earnings risk is if global supply chain disruptions result in any unforeseen components shortages.
Maintain BUY and ROE- g/COE-g Target Price of SGD2.82 (3x blended FY20-21E P/B).
Guidance Kept; Intel Deliveries > 90% on Time
On 19-Mar, AEM announced that its sales guidance of SGD360-380m for FY20 is unchanged. Further, AEM introduced 1Q20 sales guidance of a record SGD135-145m, and is cautiously confident that 1H20 will be an all-time high despite some shifts in the delivery of its sales orders due to the Covid-19 situation.
On 20-Mar, key customer Intel highlighted that it is delivering more than 90% of its chips on time. This is consistent with Intel’s early March message that operations are “relatively normal”.
Robust Balance Sheet and Solid Cash Generation
AEM’s balance sheet is robust with net cash to equity of 80%. Strong cash generation is driven by high profitability and working capital efficiency. Since 2017 (ramp-up of HDMT test handlers), cash conversion cycle has been around 15 days or less.
Intel has also kept a tight range for its days of payables outstanding (~40-50 days), even throughout the GFC, suggesting it is a good paymaster.
Accumulate on Dips
While we caution further volatility in the share price, we believe this may present buying opportunities. AEM is currently trading at 2.5x FY20E P/B, around 0.5 SD below its 3-year mean of 3x.
We continue to see AEM as a potential M&A play given its first-mover advantage in system level test. In that regard, we find is 4x FY20E EV/EBITDA valuation highly attractive.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....